Fresenius Invests to Help Humacyte Develop Implantable Blood Vessels

Fresenius has invested an additional $25 million in Humacyte Inc, to help the implantable vessel company get market approval. The new vessels, which can be used to create and repair vascular accesses, are now being tested in a clinical trial for use in dialysis.

Read the full article » | Posted 09-14-2021

Related Articles

• The National Kidney Foundation has Updated Two of its Home Dialysis Resources Posted 03-13-2025
• See How Outset Medical is Bringing Home HD into Skilled Nursing Facilities Posted 03-13-2025
• Monogram Health Held a Home Dialysis Summit for its Clinicians Posted 03-13-2025
• Annual Dialysis Conference 2025 is in Las Vegas from 3/13-16/2025 Posted 03-13-2025